LUGANO, Switzerland — Patients with diffuse large B-cell lymphoma (DLBCL) in a genetic subgroup associated with worse outcomes show significantly greater responses to treatment with the standard first ...
The Immune Atlas identifies immune signatures in MM, enhancing outcome prediction and guiding personalized therapies by ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback